Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Additive effects of montelukast in salmeterol treated moderate persistent asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002
Efficiency of once-daily mometasone furoate in school children with seasonal allergic rhinitis and severe nasal congestion Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Budesonide nasal spray alone or in combination with cetirizine in patients with severe seasonal allergic rhinitis and asthma Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
Early treatment of perennial rhinitis with budesonide or cetirizine: effect on nasal inflammation Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002
Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Mometasone furoate is safe and effective for long-term use in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 148s Year: 2001
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Health-related quality of life effects of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003
Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Inhalation of fluticasone propionate spray compared with theophilline as primary treatment for chronic mild to moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 500s Year: 2006
To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002